Bioniz Therapeutics Overview
- Year Founded
-
2010
- Status
-
Acquired/Merged
- Employees
-
13
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$330M
Bioniz Therapeutics General Information
Description
Developer of multi-cytokine inhibitory therapeutics designed to address immuno-inflammatory diseases and cancer treatment. The company develops novel peptides that selectively and simultaneously inhibit functionally redundant cytokines by blocking their unique binding interface with their shared receptor, enabling medical practitioners to treat patients with cancer and autoimmune diseases effectively.
Contact Information
Website
www.bioniz.comCorporate Office
- 5 Mason
- Suite 200
- Irvine, CA 92618
- United States
Corporate Office
- 5 Mason
- Suite 200
- Irvine, CA 92618
- United States
Bioniz Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 14-Feb-2022 | $330M | Completed | Clinical Trials - Phase 2 | ||
| 7. Merger/Acquisition | 25-Jan-2020 | Completed | Clinical Trials - Phase 2 | |||
| 6. Later Stage VC | 24-Jan-2019 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC (Series A) | 13-Apr-2017 | Completed | Clinical Trials - Phase 2 | |||
| 4. Early Stage VC | 29-Oct-2014 | Completed | Startup | |||
| 3. Early Stage VC | 10-Sep-2013 | Completed | Startup | |||
| 2. Accelerator/Incubator | 01-Aug-2012 | $500K | Completed | Startup | ||
| 1. Angel (individual) | 01-Jan-2012 | $500K | $500K | Completed | Startup |
Bioniz Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed 4 | ||||||||
| Seed 3 | ||||||||
| Seed 2 | 4,977,687 | $0.000100 | 6% | $0.2 | $0.2 | 1x | $0.2 | 13.06% |
| Seed 1 | 9,000,000 | $0.000100 | 6% | $0.01 | $0.01 | 1x | $0.01 | 23.61% |
Bioniz Therapeutics Comparisons
Industry
Financing
Details
Bioniz Therapeutics Competitors (43)
One of Bioniz Therapeutics’s 43 competitors is Marengo Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| TScan Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Bright Peak Therapeutics | Venture Capital-Backed | Allschwil, Switzerland | ||||
| CytoAgents | Venture Capital-Backed | Pittsburgh, PA |
Bioniz Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Bioniz Therapeutics Patents
Bioniz Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021297801-A1 | Antagonistic peptide targeting il-2, il-9, and il-15 signaling for the treatment of cytokine-release syndrome and cytokine storm associated disorders | Inactive | 24-Jun-2020 | ||
| CA-3186973-A1 | Antagonistic peptide targeting il-2, il-9, and il-15 signaling for the treatment of cytokine-release syndrome and cytokine storm associated disorders | Pending | 24-Jun-2020 | ||
| EP-4172175-A2 | Antagonistic peptide targeting il-2, il-9, and il-15 signaling for the treatment of cytokine-release syndrome and cytokine storm associated disorders | Inactive | 24-Jun-2020 | ||
| EP-4172175-A4 | Antagonistic peptide targeting il-2, il-9, and il-15 signaling for the treatment of cytokine-release syndrome and cytokine storm associated disorders | Inactive | 24-Jun-2020 | ||
| WO-2021262735-A2 | Antagonistic peptide targeting il-2, il-9, and il-15 signaling for the treatment of cytokine-release syndrome and cytokine storm associated disorders | Inactive | 24-Jun-2020 | C07K14/5443 |
Bioniz Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Bioniz Therapeutics Former Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Almirall | Corporation | Majority | ||
| Angel (individual) | Minority | |||
| Broadway Angels | Angel Group | Minority | ||
| Catalina Ventures | Venture Capital | Minority | ||
| Cota Capital | Venture Capital | Minority |
Bioniz Therapeutics FAQs
-
When was Bioniz Therapeutics founded?
Bioniz Therapeutics was founded in 2010.
-
Where is Bioniz Therapeutics headquartered?
Bioniz Therapeutics is headquartered in Irvine, CA.
-
What is the size of Bioniz Therapeutics?
Bioniz Therapeutics has 13 total employees.
-
What industry is Bioniz Therapeutics in?
Bioniz Therapeutics’s primary industry is Drug Delivery.
-
Is Bioniz Therapeutics a private or public company?
Bioniz Therapeutics is a Private company.
-
What is the current valuation of Bioniz Therapeutics?
The current valuation of Bioniz Therapeutics is .
-
What is Bioniz Therapeutics’s current revenue?
The current revenue for Bioniz Therapeutics is .
-
How much funding has Bioniz Therapeutics raised over time?
Bioniz Therapeutics has raised $25.6M.
-
Who are Bioniz Therapeutics’s investors?
Almirall, , Broadway Angels, Catalina Ventures, and Cota Capital are 5 of 10 investors who have invested in Bioniz Therapeutics.
-
Who are Bioniz Therapeutics’s competitors?
Marengo Therapeutics, TScan Therapeutics, Inovio Pharmaceuticals, Bright Peak Therapeutics, and CytoAgents are some of the 43 competitors of Bioniz Therapeutics.
-
When was Bioniz Therapeutics acquired?
Bioniz Therapeutics was acquired on 14-Feb-2022.
-
Who acquired Bioniz Therapeutics?
Bioniz Therapeutics was acquired by Equillium.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
